Delivery Order SPE2DR25D9113-SPE2DR26FCHV7
- Not listed
- The Defense Logistics Agency issued a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/ml on January 8, 2026, with an ultimate completion date of January 9, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded this firm fixed-price delivery order without a set-aside designation. The award represents one of numerous delivery orders issued under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a $19,950 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for FASENRA PEN 30 MG/ML. The award, issued on January 7, 2026, with an ultimate completion date of January 8, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group is performing work at its Park Ridge facility and...
- The Defense Logistics Agency (DLA) issued a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/mL, a biologic pharmaceutical product. Awarded on January 8, 2026, this firm fixed-price delivery order is issued without set-aside designation and reflects DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The place of performance is Park Ridge, Illinois, with an ultimate completion date of January 9, 2026. This delivery order...
- The Defense Logistics Agency issued a delivery order valued at $14,962.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA PEN 30 MG/ML. This firm fixed-price delivery order, awarded on January 5, 2026, with an ultimate completion date of January 6, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,481.25 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/ml on January 9, 2026, with completion targeted for January 12, 2026. This firm fixed-price delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, that specializes in...
- The Defense Logistics Agency awarded a $2,493.75 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA (benralizumab) 30 mg/mL pens. The award was issued on January 6, 2026, with an ultimate completion date of January 7, 2026, and carries no set-aside designation. This delivery order represents a routine procurement under DMS Pharmaceutical Group's broader Pharmaceutical Prime Vendor...
- The Defense Logistics Agency awarded a $9,975 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Fasenra Pen 30 mg/ml on January 7, 2026. This delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G...
- The Defense Logistics Agency awarded a $9,975 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for FASENRA (benralizumab) 30 mg/mL pen injectors. The award was issued on January 9, 2026, with an ultimate completion date of January 12, 2026, and no set-aside designation was applied. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,468.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA 30 mg/ml syringes. The contract, issued on November 7, 2025, with an ultimate completion date of November 10, 2025, carries no set-aside designation, indicating the awardee competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $7,481.25 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA (benralizumab) pen 30 mg/mL. This firm fixed-price delivery order, issued on January 7, 2026, with an ultimate completion date of January 8, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award...
- SPE2DR25D9113Indefinite Delivery Contract
- SPE2DR25D9113-SPE2DR26FCHV7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for FASENRA Pen 30 MG/ML. The award, issued on January 9, 2026, with an ultimate completion date of January 12, 2026, utilizes firm fixed-price pricing with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (SPE2DR) under the PPV-G GEN V program, awarded in November 2025 with a $499.99 billion ceiling value and completion date of December 31, 2036. The company's established performance on numerous prior delivery orders demonstrates its capability to fulfill diverse pharmaceutical requirements across therapeutic categories, including specialty biologics, oncology treatments, immunosuppressants, and routine medications supporting military healthcare operations globally. The current delivery order for FASENRA represents a routine pharmaceutical supply need within the broader scope of DMS Pharmaceutical Group's authorized product portfolio under this prime vendor contract.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 1/8/26 |